MétaCan
Menu
Back to cohort
Record W4411131729 · doi:10.1017/s109285292510031x

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease

2025· review· en· W4411131729 on OpenAlexafffund
Serene M. L. Lee, Liyang Yin, Taeho Greg Rhee, Heidi Ka Ying Lo, Sabrina Wong, Susan C. Fox, Kayla M. Teopiz, Bess Yin‐Hung Lam, Yang Jing Zheng, Gia Han Le, Rodrigo B. Mansur, Joshua D. Rosenblat, Roger S. McIntyre

Bibliographic record

VenueCNS Spectrums · 2025
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoUniversity Health NetworkBrain and Cognition Discovery FoundationQueen's University
FundersDepartment of Psychiatry, University of TorontoHealth Resources and Services AdministrationSubstance Abuse and Mental Health Services AdministrationAllerganNational Institutes of HealthBausch HealthNational Natural Science Foundation of ChinaUniversity of CambridgeCanadian Institutes of Health ResearchSunovionEisaiPurdue UniversityH. Lundbeck A/SPatient-Centered Outcomes Research InstituteUniversity of TorontoBiogenNovo NordiskSanofiNational Institute of Mental HealthPfizer
KeywordsParkinson's diseaseMedicineReceptorGlucagon-like peptide-1Glucagon-like peptide 1 receptorGlucagonPharmacologyDiseaseAgonistEndocrinologyInternal medicineDiabetes mellitusInsulinType 2 diabetes

Abstract

fetched live from OpenAlex

Parkinson's disease (PD) is a severe neurodegenerative disorder characterized by prominent motor and non-motor (e.g., cognitive) abnormalities. Notwithstanding Food and Drug Administration (FDA)-approved treatments (e.g., L-dopa), most persons with PD do not adequately benefit from the FDA-approved treatments and treatment emergent adverse events are often reasons for discontinuation. To date, no current therapy for PD is disease modifying or curative. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are central nervous system (CNS) penetrant and have shown to be neuroprotective against oxidative stress, neuroinflammation, and insulin resistance, as well as promoting neuroplasticity. Preclinical evidence suggests that GLP-1RAs also attenuate the accumulation of α-synuclein. The cellular and molecular effects of GLP-1RAs provide a basis to hypothesize putative therapeutic benefit in individuals with PD. Extant preclinical and clinical trial evidence in PD provide preliminary evidence of clinically meaningful benefit in the cardinal features of PD. Herein, we synthesize extant preclinical and early-phase clinical evidence, suggesting that GLP-1RAs may be beneficial as a treatment and/or illness progression modification therapeutic in PD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.975
Threshold uncertainty score0.945

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.326
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueCNS SpectrumsSame topicDiabetes Treatment and ManagementFrench-language works237,207